去年，Aytu Biopharma Inc表現最佳的業務類別ADHD portfolio的營收達到57.58M美元。United States的營收貢獻最高，去年達到80.91M美元。最近一個季度，截至2026-03-31，Aytu Biopharma Inc表現最佳的業務類別ADHD portfolio的營收達到9.09M美元。United States的營收貢獻最高，達到18.45M美元。

業務

營業收入

佔比

年報

年報

單季報

ADHD portfolio

Pediatric portfolio

Other

Consumer Health portfolio

Primary care and devices portfolio

FY2025

FY2024

FY2023

FY2022

FY2021

ADHD portfolio

57.58M(86.73%)

57.78M(71.34%)

46.85M(43.63%)

42.85M(44.33%)

--(--)

Pediatric portfolio

8.77M(13.21%)

7.28M(8.99%)

25.38M(23.63%)

16.08M(16.64%)

24.43M(37.22%)

Other

37.00K(0.06%)

119.00K(0.15%)

1.57M(1.46%)

2.18M(2.26%)

--(--)

Consumer Health portfolio

--(--)

15.82M(19.53%)

33.60M(31.29%)

35.55M(36.77%)

32.95M(50.21%)

Primary care and devices portfolio

--(--)

8.25M(12.57%)

地區

營業收入

佔比

年報

年報

單季報

United States

International

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

80.91M(99.89%)

106.92M(99.55%)

94.61M(97.87%)

60.69M(92.47%)

24.98M(90.40%)

6.46M(88.28%)

International

91.00K(0.11%)

481.00K(0.45%)

2.06M(2.13%)

4.95M(7.53%)

2.65M(9.60%)

858.00K(11.72%)